Newly Diagnosed Ependymoma Study

Newly Diagnosed Ependymoma Study

Share this:

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.

PROTOCOL ID

COG # ACNS0831

PROTOCOL DESCRIPTION

This study is for patients newly diagnosed with ependymoma. Ependymoma is a type of cancer that occurs in the brain. This slow-growing tumor begins in cells that line the fluid-filled spaces of the brain (called ventricles) or the fluid-filled space down the center of the spinal cord (the central canal). The current standard of treatment for newly diagnosed ependymoma includes surgery to remove as much of the tumor as possible, and radiation therapy.

This study wants to see if a short course of chemotherapy therapy can kill any remaining tumor cells for patients whose tumor was only partially removed by surgery. Treatment with chemotherapy after surgery is experimental.

This study also wants to see if patients whose remaining tumor was killed by the short course of chemotherapy and/or removed by a second surgery and whose tumor was not in the upper part of the brain and does not have favorable-looking cells see if treatment with chemotherapy after radiation therapy will work better than standard treatment to keep the tumor from coming back. Treatment with chemotherapy after radiation therapy is experimental.

ELIGIBILITY CRITERIA

  • Patients must be greater than 12 months of age and less than 21 years of age at the time of study enrollment.
  • Patients must be newly diagnosed with intracranial ependymoma. Patients with classic ependymoma (WHO II) or anaplastic ependymoma (WHO III) are eligible, as are various subtypes described as clear cell, papillary, cellular or a combination of the above.
  • Patients with evidence of metastatic disease by MRI or CSF cytology are NOT eligible.

Primary Investigator(s)

Mandy Atkinson, M.D.

Contact Information

Wendy McCarty, Clinical Research Coordinator
Office: 540-981-7376
wpmccarty@carilionclinic.org